Stock watch as on Feb 27, 2008

The Kolkata-based company’s market cap was Rs 213 crore as on 20 February 2008 on an equity capital of Rs 16.71 crore. It has all the potential for acceleration and is projecting compounded annualised revenue growth of 40% for the next three years. At the current market price of Rs 130, the stock has given 4.7% return in the past one year.

Core business Construction in the core infrastructure sector such as the railways, road, urban, marine, power and aviation verticals.

For current stock prices and more details, click here

This Mumbai-based company, a leader in the niche segment of injectable formulations, is on a roll. With a loyal clientele of multinational companies and large Indian pharma companies, the management is optimistic of more than doubling the revenue in two years—from Rs 120 crore in 2007-8 to Rs 250 crore in 2009-10. At Rs 129, the stock has risen 166% in past one year.

Core business Manufacturing injectable drugs for MNCs and large Indian pharma companies.

For current stock prices and more details, click here

A growth story is cooking up in this Lalbhai Group company. It has created nine popular phosgene-based derivatives and four more are in the pipeline. Besides, it has a licenced capacity of 5,000 TPA compared to an installed capacity of 1,000 TPA—an edge in a business with protected licensing. At Rs 68, the stock has fallen 26.5% in the past one year.

Core business Manufacturing pharmaceuticals and agro-chemicals.

For current stock prices and more details, click here

This new kid on the onland seismic services turf has bagged large orders from ONGC and Oil India. The company has embarked on a capex of Rs 25 crore for acquiring additional three crews. It plans to acquire a drilling rig and apply for exploration and production operations in marginal fields. At Rs 200, the stock has risen 478% in past one year.

Core business Provides specialist services to petroleum exploration companies.

For current stock prices and more details, click here